Michael Tippie

Michael Tippie is an executive with more than 25 years of operational, venture and consulting experience. Most recently, Michael was CEO of TomegaVax, which was merged with Vir Biotechnology in 2016 and immediately thereafter did a $150 million Series A venture financing (ARCH Ventures, Gates Foundation). Michael has held senior executive roles in seven start-ups and has managed accounting, market research, business development and sales staffs. He has completed complex deals with large pharma companies as well as numerous private and public financings (including IPOs). Michael’s venture experience comes from stints at Norwest Venture Partners ($4 billion megafund), Medical Innovation Partners ($35 million seed-stage medical device focused fund) and Milk Street Ventures (secondary venture purchases). Michael holds a BA in Chemistry from Reed College and an MS in Chemistry from the University of Washington as well as an MBA from the MIT Sloan School of Management.